IGC PHARMA INC
IGCNYSE AMERICANTrading Snapshot
- Day Range
- $916.47 – $937.65
- 52-Week Range
- $0.24 – $0.50
- Volume
- $3.01B
- Avg Volume
- $2.09B
- Shares Outstanding
- 104.4M
- Next Earnings
- Oct 20, 2026
Fundamentals Snapshot
- Annual Revenue
- $1M
- Last Q Revenue
- $317,000
- P/E Ratio
- —
- P/S Ratio
- 22.8x
- EPS (TTM)
- $-0.07
- Dividend Yield
- —
Why Investors Own IGC
- ✓High-growth profile — revenue up +43.9% YoY with expanding US Equity exposure.
- ✓Healthy economics — 41% gross margin and 4% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About IGC PHARMA INC
IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage. Beyond its therapeutic development efforts, IGC Pharma also explores the application of artificial intelligence (AI) to advance Alzheimer's research. Established on April 29, 2005, by Ram Mukunda, the company maintains its principal office in Potomac, Maryland.